Cadrenal Therapeutics Unveils Cardiac Critical Care Franchise, Seeks Partners For Late-Stage Cardiovascular Assets
Cadrenal Therapeutics Inc CVKD
$2.01
▼ -3.83%
($-0.08)
🎈 Low Float
🗓️ Earnings Next Week
Open
$2.08
Prev Close
$2.09
Day Range
$1.97 – $2.11
52W Range
$1.86 – $14.64
Market Cap
$6.23M
Beta
1.82
EPS (TTM)
$-5.65
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2023-01-20 |
| Shares Out. | 3,100,000 |
| Website | cadrenal.com/ ↗ |
| Phone | 13026587581 |
| Employees | 5 |
| Net Income | -$2.5M |
| Free Cash Flow | -$11.0M |
| Total Assets | $2.9M |
| Total Liabilities | $1.1M |
| Equity | $1.8M |
About Cadrenal Therapeutics Inc
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
Cadrenal Therapeutics Inc is a publicly traded company under the ticker symbol CVKD on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-07-01)